Cytokine Signatures Induced by Epstein-Barr Virus Antigens in Multiple Sclerosis: Elucidating the Role of B-Cell and T-Cell Hyperactivation in Disease Relapse
Source abstract
Abstract
Objectives: To investigate the profile of Th1- and Th2-type cytokines in response to Epstein–Barr virus (EBV) antigens and to correlate this immune signature with clinical relapses in Multiple Sclerosis (MS). Specifically, we aimed to evaluate the cellular and humoral immune response following stimulation with a pool of lytic and latent EBV proteins. Methods: We employed ELISpot and ELISA to quantify Interferon-gamma (IFN-γ), Interleukin-18 (IL-18), Interleukin-10 (IL-10), and the B-cell activation marker soluble CD23 (sCD23). Measurements were performed on peripheral blood mononuclear cells (PBMCs) from MS patients and controls following stimulation with EBV peptide antigens. Results: MS patients exhibited significantly higher levels of all tested cytokines compared to controls. A statistically significant positive correlation was noted between IL-10 and sCD23 levels (p < 0.03), with significant correlations also found between IL-10 and IFN-γ (r = −0.56) and between IFN-γ and IL-18 (p < 0.02), a finding that warrants cautious interpretation. Crucially, both IL-10 and sCD23 levels strongly correlated with the Expanded Disability Status Scale (EDSS) score (p = 0.0003 and p = 0.0001, respectively). Conclusions: Our findings suggest a chronic, dysregulated immune response to EBV antigens in MS patients, characterized by the co-activation of inflammatory Th1 pathways and robust B-cell activation. These results support a pathogenetic model where the EBV-specific immune response, perpetuated by infected B-cells, may directly contribute to the immunopathological processes driving central nervous system (CNS) damage and clinical relapses.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Multiple Sclerosis Research Studies · Polyomavirus and related diseases · Herpesvirus Infections and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
I UOC Emerging Infectious Disease at High Contagiousness, P.O. D. Cotugno Hospital, “Ospedali dei Colli”, 80131 Naples, Italy
VII UOC Infectious Disease of Geriatric Age, P.O. D. Cotugno Hospital, “Ospedali dei Colli”, 80131 Naples, Italy
Virology and Microbiology, P.O. D. Cotugno Hospital, “Ospedali dei Colli”, 80131 Naples, Italy
Neurological Department, Hermes University, 00187 Rome, Italy
References (22)
Show source-provided references
1. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis10.1126/science.abj8222 ↗
2. Hedström, A.K. (2023). Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection. Front. Immunol., 14.10.3389/fimmu.2023.1212676 ↗
3. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain10.1084/jem.20071030 ↗
4. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM10.1038/s41586-022-04432-7 ↗
5. Epstein-Barr virus in multiple sclerosis: Theory and emerging immunotherapies10.1016/j.molmed.2019.11.003 ↗
6. Broader anti-EBV TCR repertoire in multiple sclerosis: Disease specificity and treatment modulation10.1093/brain/awae244 ↗
7. Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis10.1038/cti.2016.87 ↗
8. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions10.1212/WNL.0b013e31823ed057 ↗
9. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis10.1056/NEJMoa1601277 ↗
10. Interleukin-10 and tumor necrosis factor-alpha: Mode of immunomodulation in multiple sclerosis10.1179/016164105X39879 ↗
11. Interleukin-10 and Interleukin-12 Modulation in Patients with Relapsing-Remitting Multiple Sclerosis on Therapy with Interferon-beta 1a10.1080/08923970802302753 ↗
12. Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate10.1016/j.metabol.2015.05.001 ↗
13. Immune-inflammatory and oxidative and nitrosative stress biomarkers of depression symptoms in subjects with multiple sclerosis: Increased peripheral inflammation but less acute neuroinflammation10.1007/s12035-015-9443-4 ↗
14. Reassessing B cell contributions in multiple sclerosis10.1038/s41590-018-0135-x ↗
15. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis10.1056/NEJMoa1606468 ↗
16. Regulatory T cells in autoimmune disease10.1038/s41590-018-0120-4 ↗
17. Regulatory B cells: Origin, phenotype, and function10.1016/j.immuni.2015.04.005 ↗
18. Smatti, M.K., Cyprian, F.S., Nasrallah, G.K., Al Thani, A.A., Almishal, R.O., and Yassine, H.M. (2019). Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses, 11.10.3390/v11080762 ↗
19. Molecular mimicry and autoimmunity10.1016/j.jaut.2018.10.012 ↗
20. Diversity and plasticity of self recognition during the development of multiple sclerosis10.1172/JCI119331 ↗
21. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis10.1172/jci.insight.124714 ↗
22. Epstein-Barr virus and multiple sclerosis10.1038/s41579-022-00770-5 ↗